Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma.

Autor: Aschero R; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Ganiewich D; Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina., Lamas G; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Restrepo-Perdomo CA; Pathology Service, Hospital Sant Joan de Deu, Barcelona, Spain., Ottaviani D; SIREDO Center, Institut Curie and University Paris Cité, Paris, France., Zugbi S; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Camarero S; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Néspoli E; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Vilanova MC; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Perez-Jaume S; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Pascual-Pasto G; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Sampor C; Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Grigorovski N; Department of Pediatric Oncology, Clinical Division, National Institute of Cancer, Rio de Janeiro, Brazil., Salas B; Department of Pediatric Oncology, Hospital del Niño Manuel A. Villarroel, Cochabamba, Bolivia., Suñol M; Pathology Service, Hospital Sant Joan de Deu, Barcelona, Spain., Carcaboso AM; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Mora J; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., de Dávila MTG; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Doz F; SIREDO Center, Institut Curie and University Paris Cité, Paris, France., Radvanyi F; SIREDO Center, Institut Curie and University Paris Cité, Paris, France., Abramson DH; Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA., Llera AS; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina.; Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina., Schaiquevich PS; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Lubieniecki F; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Chantada GL; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain.; Hematology Oncology Service, Hospital Pereyra Rossell, Montevideo, Uruguay.

Publikováno v: Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Jan; Vol. 71 (1), pp. e30717. Date of Electronic Publication: 2023 Oct 09.

Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity.

Autor: Zubiaur P; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA., Soria-Chacartegui P; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain., Boone EC; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA., Prasad B; Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA., Dinh J; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA., Wang WY; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA., Zugbi S; Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Rodríguez-Lopez A; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain., González-Iglesias E; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain., Leeder JS; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA., Abad-Santos F; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., Gaedigk A; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Nov; Vol. 114 (5), pp. 1033-1042. Date of Electronic Publication: 2023 Aug 11.

Tridimensional Retinoblastoma Cultures as Vitreous Seeds Models for Live-Cell Imaging of Chemotherapy Penetration

Autor: Winter U, Aschero R, Fuentes F, Buontempo F, Zugbi S, Sgroi M, Sampor C, Abramson DH, Carcaboso AM, Schaiquevich P

Publikováno v: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

A preclinical model could aid in understanding retinoblastoma vitreous seeds behavior, drug penetration, and response to chemotherapy to optimize patient treatment. Our aim was to develop a tridimensional in vitro model of retinoblastoma vitreous see

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5e327b5d669411a0a6fbc16a7068ffca
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16046

Clinical, Genomic, and Pharmacological Study of MYCN -Amplified RB1 Wild-Type Metastatic Retinoblastoma.

Autor: Zugbi S; Precision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.; National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina., Ganiewich D; Precision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.; Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires 1405, Argentina., Bhattacharyya A; Department of Paediatric Haematology and Oncology, Tata Memorial Hospital, Kolkata 700160, India., Aschero R; Precision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.; National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina., Ottaviani D; Institut Curie; PSL Research University, Centre National de la Recherche Scientifique (CNRS), UMR144, Equipe Ligue Contre le Cancer, 75005 Paris, France., Sampor C; Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Cafferata EG; National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.; Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires 1405, Argentina., Mena M; Precision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Sgroi M; Ophthalmology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Winter U; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Lamas G; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Suñol M; Pathology Service, Hospital Sant Joan de Deu, 08950 Barcelona, Spain., Daroqui M; Cytogenetics Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Baialardo E; Cytogenetics Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Salas B; Paediatric Oncology Service, Hospital Asencio Villaroel, Cochabamba 2500, Bolivia., Das A; Department of Paediatric Haematology and Oncology, Tata Memorial Hospital, Kolkata 700160, India., Fandiño A; Ophthalmology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Francis JH; Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA., Lubieniecki F; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina., Lavarino C; Pediatric Hematology and Oncology Service, Hospital Sant Joan de Deu, 08950 Barcelona, Spain.; Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, Fundación Sant Joan de Déu, 08950 Barcelona, Spain., Garippa R; Gene editing and screening core facility, Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA., Podhajcer OL; National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.; Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires 1405, Argentina., Abramson DH; Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA., Radvanyi F; Institut Curie; PSL Research University, Centre National de la Recherche Scientifique (CNRS), UMR144, Equipe Ligue Contre le Cancer, 75005 Paris, France., Chantada G; Precision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.; National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.; Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, Fundación Sant Joan de Déu, 08950 Barcelona, Spain., Llera AS; National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.; Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires 1405, Argentina., Schaiquevich P; Precision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.; National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.

Publikováno v: Cancers [Cancers (Basel)] 2020 Sep 22; Vol. 12 (9). Date of Electronic Publication: 2020 Sep 22.

Retinoblastoma – A comprehensive review, update and recent advances.

Autor: Nag, Adwaita¹, Khetan, Vikas^2,3 drkhetan@gmail.com

Publikováno v: Indian Journal of Ophthalmology. Jun2024, Vol. 72 Issue 6, p778-788. 11p.